Mergers & Acquisitions ·
Repligen completes acquisition of BioLife Solutions for $11.25 cash and 0.1442 shares per share
RGENRepligen Corp
Repligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., on October 6, 2026. Under the terms of the merger agreement, holders of BioLife common stock received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The transaction expands Repligen's presence in the cell therapy market by adding BioLife’s biopreservation media portfolio, which supports commercially approved therapies and clinical trials. BioLife has ceased to exist as a separate legal entity and its stock will be delisted from Nasdaq. Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems for manufacturing biological drugs.